An evaluation of the strengths and weaknesses of a register of newly diagnosed rheumatoid arthritis, 1986-2010

Rheumatology

Volumn 50, Issue 1, 2011, Pages 176-183

  Young, Adam ^a   Dixey, Josh ^b   Williams, Peter ^c   Prouse, Peter ^d   Cox, Nigel ^e   Kiely, Patrick ^f   Williams, Richard ^g   Walsh, David ^h,i  

^a St Albans City Hospital   (United Kingdom)

^b NEW CROSS HOSPITAL   (United Kingdom)

^c MEDWAY MARITIME HOSPITAL   (United Kingdom)

^d NORTH HAMPSHIRE HOSPITAL   (United Kingdom)

^e ROYAL HAMPSHIRE COUNTY HOSPITAL   (United Kingdom)

^f ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^g HEREFORD COUNTY HOSPITAL   (United Kingdom)

^h NOTTINGHAM CITY HOSPITAL   (United Kingdom)

ⁱ KING S MILL HOSPITAL   (United Kingdom)

Author keywords

Disease registry; DMARDs; RA outcomes; Rheumatoid arthritis

Indexed keywords

HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; STEROID;

ARTICLE; CLINICAL PRACTICE; COMORBIDITY; CONTROLLED CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE REGISTRY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; COHORT STUDIES; DATABASES, FACTUAL; EARLY DIAGNOSIS; GREAT BRITAIN; HUMANS; IRELAND; REGISTRIES;

EID: 79951687193     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq318     Document Type: Article

References (29)

1. Wolfe F, Lassere M, van der Heijde D et al. Preliminary core set of domains and reporting requirements for longitudinal observational studies in rheumatology. J Rheumatol 1999;26:484-9.
2. British Society for Rheumatology Biologics Register (BSRBR). www.medicine.manchester.ac.uk/arc/BSRBR (8 September 2010, date last accessed).
3. Scottish Intercollegiate Guidelines Network. Management of early RA. Pub No. 48, SIGN, 2000. www.sign.ac.uk/guidelines/fulltext/48/index.html (8 September 2010, date last accessed).
4. Luqmani R, Hennell S, Estrach C et al. British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of rheumatoid arthritis (the first two years). Rheumatology 2006;45:1167-9.
5. Arthritis & Musculoskeletal Alliance. www.arma.uk.net (8 September 2010, date last accessed).
6. National Institute for Health & Clinical Excellence. www.nice.org.uk/CG79 (8 September 2010, date last accessed).
7. Jacoby RK, Jayson MIV, Cosh JA. Onset, early stages, and prognosis of rheumatoid arthritis: a clinical study of 100 patients with 11 year follow up. Br Med J 1973;2:96-100.
8. Corbett M, Dalton S, Young A, Silman A, Shipley M. Factors predicting death, survival & function and functional outcome in a prospective study of early rheumatoid disease over fifteen years. Br J Rheumatol 1993;32:717-23.
9. Young A. Short-term outcomes in recent onset RA. Br J Rheumatol 1995;34(Suppl. 2):79-86.
10. Young A, Dixey J, Cox N et al. How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS). Rheumatology 2000;39:603-11.
11. ERAS Study Group. Socioeconomic deprivation and RA: what lessons for the health service? Ann Rheum Dis 2000; 59:794-9.
12. Arnett FC, Edworthy SM, Bloch DA et al. The ARA 1987 revised criteria for classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
13. van Gestel AM, van Riel PL. Evaluation of early rheumatoid arthritis disease activity and outcome. Baillieres Clin Rheumatol 1997;11:49-63.
14. ICH GCP 1996. www.ich.org/LOB/media/MEDIA482.pdf (8 September 2010, date last accessed).
15. Office of National Statistics (ONS). www.statistics.gov.uk (8 September 2010, date last accessed).
16. Young A, Koduri G, Batley M et al. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology 2007;46:350-7.
17. Koduri G, Norton S, Young A. Interstitial lung disease in RA has a poor prognosis. Rheumatology 2010;46:350-7.
18. Koduri G, Young A, Williams R et al. Evidence that vasculitis complicating rheumatoid arthritis (RA) may be becoming less common. An analysis of extra articular features (ExRA) in two early RA inception cohorts. Arthritis Rheum 2009;60(Suppl 10):968.
19. National Audit Office report on patients with RA. http://www.nao.org.uk/publications/0809/rheumatoid_arthritis.aspx (8 September 2010, date last accessed).
20. Kiely P, Williams R, Walsh D, Young A. For, early rheumatoid arthritis network. Contemporary patterns of care and disease activity outcome in early rheumatoid arthritis: the ERAN cohort. Rheumatology 2009;48:57-60.
21. Kremer JM. Rationale use of new and existing disease-modifying agents in rheumatoid arthritis. Ann Intern Med 2001;134:695-706.
22. Consensus statement. Ann Rheum Dis 2000;59(Suppl. I): 1-2.
23. Hospital Episodes Statistics (HES). www.hesonline.nhs.uk (8 September 2010, date last accessed).
24. James D, Young A, Kulinskaya E et al. Orthopaedic intervention in early rheumatoid arthritis. Occurrence and predictive factors in an inception cohort of 1064 patients followed for 5 years. Rheumatology 2004;43:369-76.
25. National RA Society. www.nras.org.uk (8 September 2010, date last accessed).
26. van der Woude D, Young A, Jaykumar K et al. Prevalence of and predictive factors for sustained DMARD-free remission in RA: results from two large early arthritis cohorts. Arthritis Rheum 2009;60:2262-71.
27. Young A, Dixey J, Kulininska E et al. Which patients with early RA stop working? Results from a 5 yr inception cohort of 732 patients. Ann Rheum Dis 2002;61:335-40.
28. Rachapalli SM, Walsh D, Williams R, Young A, Kiely P, Choy E. Factors influencing DMARD choice in early RA. Do prognostic factors play a role? Rheumatology 2010;49: 1267-71.
29. Kobelt G, Jonsson L, Lindgren P, Young A, Eberhardt K. Modelling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of RA. Arthritis Rheum 2002;46:2310-9.